{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458639521
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD125]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = investigational
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1044511-01-4
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 71492GE1FX
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09874
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6492 | H=10060 | N=1724 | O=2028 | S=42
| molecular_weight = 146.0 kg/mol
}}
'''Benralizumab''' ([[International Nonproprietary Name|INN]]) is a [[monoclonal antibody]] which is being developed by [[MedImmune]] for the treatment of [[asthma]]. It is directed against the alpha-chain of the [[interleukin-5 receptor]] ([[CD125]]).<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/benralizumab.pdf Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab]</ref><ref>{{Cite journal 
| last1 = Catley | first1 = M. C. 
| title = Asthma & COPD--IQPC's Second Conference 
| journal = IDrugs : the investigational drugs journal 
| volume = 13 
| issue = 9 
| pages = 601–604 
| year = 2010 
| pmid = 20799138
}}</ref>

Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their [[primary endpoint]]s in 2016.<ref>[http://seekingalpha.com/news/3206982-astrazenecas-benralizumab-reduces-asthma-exacerbations-51-percent-two-late-state-studies AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016]</ref><ref>{{cite journal|doi=10.1056/NEJMoa1703501|pmid=28530840|title=Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma|journal=New England Journal of Medicine|volume=376|issue=25|pages=2448|year=2017|last1=Nair|first1=Parameswaran|last2=Wenzel|first2=Sally|last3=Rabe|first3=Klaus F.|last4=Bourdin|first4=Arnaud|last5=Lugogo|first5=Njira L.|last6=Kuna|first6=Piotr|last7=Barker|first7=Peter|last8=Sproule|first8=Stephanie|last9=Ponnarambil|first9=Sandhia|last10=Goldman|first10=Mitchell}}</ref>

== References ==
{{Reflist}}

{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{monoclonal-antibody-stub}}
{{respiratory-system-drug-stub}}